Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study

 

KS Eom, SJ Kim, JJ Lee, C Suh, JS Kim, SS Yoon… - BioMed Research …, 2014

... pain in terms of total VAS after cycle 4, the proportion of patients who reported severe bone pain
(VAS ) decreased ... M. Kaiser, C. Müller et al., “Bortezomib increases osteoblast activity in myeloma
patients irrespective of response to treatment,” European Journal of Haematology ...